Daniel Tennenbaum, MD

GU Oncology Now

For patients with elevated prostate-specific antigen (PSA) levels after radical prostatectomy, 18F-prostate-specific membrane antigen (PSMA)-1007 positron emission tomography/computed tomography (PET/CT) has a high detection rate for pathological findings, according to a study to be published in the January 2022 issue of Translational Oncology.For the study, Xing Zhou, from Sichuan Cancer Hospital in Chengdu, China, and colleagues enrolled 71 patients with prostate cancer after radical prostatectomy to examine the value of 18F-PSMA-1007 PET/CT. Patients had a median PSA level of 1.27 ng/mL. After injection of 18F-PSMA-1007, all patients underwent whole-body PET/CT imaging.The researchers found that 56 patients (79 percent) had at least one pathological finding on 18F-PSMA-1007 PET/CT. Among patients with PSA of &le;0.5, 0.51 to 1.0, 1.1 to 2.0, and &gt;2.0 ng/mL, the rates of positive scans were 50, 80, 100, and 100 percent, respectively. Patients had a median Gleason score of 8; a higher Gleason score (&ge;8 versus &le;7) yielded significantly higher detection rates (88.9 versus 58.3 percent). For patients with PSA of &le;0.5, 0.51 to 1.0, 1.1 to 2.0, and &gt;2.0 ng/mL, the median maximum standardized uptake value (SUVmax) of positive findings was 4.51, 4.27, 11.50, and 14.08, respectively. Patients with PSA &gt;2.0 ng/mL had significantly higher median SUVmax than those with PSA &le;2.0 ng/mL (14.08 versus 6.13).&ldquo;We found that 18F-PSMA-1007 PET/CT exhibited a high sensitivity in detecting PSMA-positive lesions,&rdquo; the researchers wrote. &ldquo;We successfully localized the recurrence for 56 patients, with the detection rates of 79 percent.&rdquo;

18F-PSMA-1007 IDs Pathologic Lesions After Radical Prostatectomy

Radioligand therapy prostate-specific membrane antigen

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe